apremilast sold brand name otezla among others medication treatment certain types psoriasis psoriatic arthritis drug acts selective inhibitor enzyme phosphodiesterase inhibits spontaneous production tnfalpha human rheumatoid synovial taken apremilast indicated united states treatment adults active psoriatic arthritis adult patients plaque psoriasis candidates phototherapy systemic therapy adults oral ulcers associated behçets european union apremilast alone combination diseasemodifying antirheumatic drugs dmards indicated treatment active psoriatic arthritis psa adults inadequate response intolerant prior dmard also indicated treatment moderate severe chronic plaque psoriasis adults failed respond contraindication intolerant systemic therapies including cyclosporine methotrexate psoralen ultravioleta apremilast studied treatment alcoholuse european union drug contraindicated pregnancy mice monkeys receiving high doses apremilast observed suffer miscarriages pregnancy us may used pregnant women potential benefit justifies potential risk diarrhea occurs people taking apremilast severe gastrointestinal symptoms occur typically start within first weeks worsening depression suicidal thoughts mood changes may occur weight loss associated apremilast reports clinical studies indicated decrease body weight patients taking apremilast compared patients taking common usually mild moderate adverse effects associated apremilast include headache back pain nausea diarrhoea fatigue nasopharyngitis upper respiratory tract concurrent use strong cytochrome enzyme inducers shown decrease exposure apremilast result reduced loss efficacy apremilast using simultaneously strong enzyme inducers including rifampicin phenobarbital carbamazepine st johns wort apremilast smallmolecule inhibitor enzyme breaks cyclic adenosine monophosphate inflammatory cells dominant enzyme responsible reaction resulting increase camp levels downregulates expression number proinflammatory factors tumor necrosis factor alpha tnfα interleukin interleukin many others upregulates antiinflammatory interleukin ex vivo models arthritis specifically identified downstream target importance individual factors clinical effect apremilast apremilast absorbed well gut independently food intake reaches peak blood plasma concentrations hours plasma protein binding metabolised liver mainly via enzyme minor extent via main metabolite odesmethylapremilast halflife hours substance eliminated kidney feces mainly form metabolites original substance found urine apremilast phthalimide derivative white pale yellow nonhygroscopic powder practically insoluble water buffer solutions wide ph range soluble lipophilic solvents acetone acetonitrile butanone dichloromethane vitro apremilast reduces activity leading increase cyclicadenosine monophosphate camp concentrations immune nonimmune cell types partially inhibiting production many proinflammatory cytokines tnfα ifnγ elevating production antiinflammatory cytokine inhibition potency apremilast tnfα production similar celgene reported seven kinds crystal forms b c e f g thought crystal form b thermodynamically stable anhydrous form however utopharm reported another thermodynamically stable anhydrous crystal form ii crystal form apremilast approved us food drug administration fda treatment adults active psoriatic arthritis moderate severe plaque psoriasis approved oral ulcers associated behçets apremilast taken otezla available us dispensed network specialty estimated wholesale price year austria drug available pharmacies year treatment costs health insurances india drug available pharmacies year treatment costs celgene made otezla available uk amgen acquired otezla celgene otezla generated billion apremilast approved use european union january generic versions medication available april american court case confirmed amgens patents otezla delaying introduction generics least date httpsenwikipediaorgwikiapremilast